March 22, 2023 03:43 PM EDTUpdated March 23, 08:45 AM
Pharma
FDA+

In­cyte wins ac­cel­er­at­ed ap­proval for PD-1 in rare skin can­cer

Nicole DeFeudis

Editor

In­cyte tout­ed an ac­cel­er­at­ed ap­proval for its PD-1 reti­fan­limab in a rare skin can­cer on Wednes­day, rough­ly a year and a half af­ter the drug …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

A service from the Financial Times